SCHEMBL3774233

SCHEMBL3774233

COc1ccc(OC)c(CC(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.57
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 3/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.49
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
NPC1 O15118 1/20 0.46
CBX7 O95931 1/20 0.46
CDYL2 Q8N8U2 1/20 0.46
CDYL Q9Y232 1/20 0.46
HSD17B10 Q99714 1/20 0.45
SIGMAR1 Q99720 2/20 0.45
ACHE P22303 1/20 0.45
KDM2B Q8NHM5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3780644 0.92 ALDH1A1 (0.55) RAB9AKMT2AALDH1A1TSHRMEN1
SCHEMBL3773681 0.89 KDM4E (0.55) RAB9AKMT2AALDH1A1TSHRMEN1
SCHEMBL3773641 0.86 KMT2A (0.64) KMT2AALDH1A1TSHRMEN1KDM4E
SCHEMBL3772205 0.86 ALDH1A1 (0.50) RAB9AKMT2AALDH1A1TSHRMEN1
SCHEMBL3777237 0.84 SMN1; SMN2 (0.64) RAB9AKMT2AALDH1A1TSHRKDM4E
SCHEMBL3769405 0.84 KDM2B (0.54) RAB9AKMT2AALDH1A1TSHRKDM4E
SCHEMBL3769008 0.84 RAB9A (0.49) RAB9AKMT2AALDH1A1TSHRMEN1
SCHEMBL3769019 0.84 RAB9A (0.49) RAB9AKMT2AALDH1A1TSHRMEN1
SCHEMBL3780606 0.83 HTT (0.57) KMT2AALDH1A1TSHRMEN1KDM4E
SCHEMBL3773282 0.82 CCR3 (0.43) RAB9AKMT2AALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 RAB9A 3824/4885KMT2A 242/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.